In recent years, anti‐PD‐1/PD‐L1 antibodies have shown efficacy for advanced NSCLC patients in previous clinical trials and anti‐PD‐1/PD‐L1 therapy has been recommended as a standard treatment for advanced‐stage NSCLC.18, 19, 20, 21, 22, 23. Here, CD274 is linked to non-small cell lung carcinoma.